Skip to content

IMPAHCT Study Investigates a New Treatment for Pulmonary Hypertension

Search Clinical Trials

Trial Objectives

Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is a serious condition that makes it more difficult for the heart to pump blood through the body. Current treatment options help relieve PAH symptoms, but do not target the underlying causes of the condition. The IMPAHCT clinical trial is evaluating an investigational medication for pulmonary arterial hypertension (PAH) called AV-101 to find out what dose is safe and tolerable, and works best in people with PAH.

Study participants will take either AV-101 or a placebo (a treatment containing no active medication) twice a day. During study visits or phone calls, participants will complete assessments to help researchers understand how the medication may be helping them and any side effects that might occur. Participants can continue taking any PAH medications they are currently taking.

Who Can Participate

Adults ages 18-75 with a documented pulmonary arterial hypertension (PAH) diagnosis, who have been receiving a minimum of two PAH medications for at least 90 days.

Age: 18-75 Gender: Any

Estimated Time Commitment

Five study visits over 24 weeks, plus an introductory screening visit and four phone calls

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Aerovate Therapeutics, Inc.

Principal Investigators

Marjorie Patricia George

Marjorie Patricia George, MD


  • Darlene Kim

    Darlene Kim, MD, FACC

  • Vera Pillitteri

    Vera Pillitteri, DNP, FNP-BC

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required